Methods and compounds for identifying glycosyltransferase inhibitors

US10106833B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10106833-B2
Application numberUS-201314390857-A
CountryUS
Kind codeB2
Filing dateMar 13, 2013
Priority dateApr 6, 2012
Publication dateOct 23, 2018
Grant dateOct 23, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (I): or a salt thereof, wherein R 1 is -L-R P , —C(O)NH-L-R P , —CH 2 O-L-R P , or —C(O)O-L-R P ; R 2 and R 3 are independently hydrogen, optionally substituted aliphatic, —OR 9 , —N(R 8 ) 2 , or —C(O)NHR 8 ; R 4 is hydrogen or —WR 4a ; W is —O— or —NH—; R 4a is hydrogen, a hydroxyl protecting group, optionally substituted aliphatic, —C(O)R 10 , —C(O)NHR 8 , —C(═NR 8 )NHR 8 , or —C(O)OR 9 ; R 5 is hydrogen or —NHR 8 ; R 6 is hydrogen, —CH 3 , —CH 2 OR 9 , or —CH 2 OR CX ; wherein R CX is a carbohydrate moiety; R 7 is hydrogen, —OR 9 , or —N(R 8 ) 2 ; each R 8 is independently hydrogen, an amino protecting group, —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, or two R 8 groups on the same nitrogen may be taken together to form an optionally substituted heterocyclyl; each R 9 is independently hydrogen, a hydroxyl protecting group, —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; each R 10 is independently optionally substituted aliphatic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl; R a and R b are independently hydrogen or a hydroxyl protecting group; G is an optionally substituted C 1-16 aliphatic group, wherein 0 to 10 methylene units are optionally replaced with —O—, —NR x —, —S—, —C(O)—, —C(═NR x ), —S(O)—, —SO 2 —, —N═N—, —C═N—, —N—O—, an optionally substituted arylene, an optionally substituted heterocyclylene, or an optionally substituted heteroarylene; wherein each instance of R x is independently hydrogen, optionally substituted aliphatic, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; or G is a group of Formula (a), (b), or (c): wherein a is 3, 4, or 5; wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 are each independently hydrogen or halogen; d is an integer between 1 and 25, inclusive; and e is an integer of between 2 and 25, inclusive; provided the sum of d and e is greater than 16; or wherein Y is —O—, —S—, —NR Y —, or an optionally substituted methylene group, wherein R Y is hydrogen, optionally substituted aliphatic, or an amino protecting group; each instance of R c is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —OR e , —SR e , —NHR e , or —N(R e ) 2 , wherein each instance of R e is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R e groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; each instance of R d is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —OR f , —SR f , —NHR f , or —N(R f ) 2 , wherein each instance of R f is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R f groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; R z is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —OR g , —SR g , —NHR g , or —N(R g ) 2 , wherein each instance of R g is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two R g groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; each instance of n is, independently, 0, 1, 2, 3, or 4; each instance of m is, independently, 0, 1, 2, 3, or 4; and x is 1, 2, 3, 4, 5, or 6; R YY is hydrogen or —OR XX ; R XX is hydrogen, a hydroxyl protecting group, or a group of formula: wherein R 11 is hydrogen, optionally substituted aliphatic, —C(O)NHR 8 , —CH 2 OR 9 , or —C(O)OR 9 ; R 12 and R 13 are independently hydrogen, optionally substituted aliphatic, —OR 9 , —N(R 8 ) 2 , or —C(O)NHR 8 ; R 14 is hydrogen or —NHR 8 ; R 15 is hydrogen, —C(O)NHR 8 , —CH 2 OR 9 , or —C(O)OR 9 ; R 16 is hydrogen or —OR 9 ; R 17 is hydrogen or —OR 9 ; R 18 is hydrogen or —OR 9 ; R 19a is hydrogen or —OR 9 ; R 19b is hydrogen or —OR 9 ; wherein a hydrogen radical on the compound of Formula (I) is replaced with -L-R P ; L is a covalent bond, —NR y —, —N(R y )C(O)—, —N(R y )C(O)N(R y )—, —N(R y )C(S)N(R y )—, —C(O)N(R y )—, —N(R y )SO 2 —, —SO 2 N(R y )—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, optionally substituted cycloalkylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, or an optionally substituted aliphatic linker, wherein one or more methylene units of the aliphatic linker are optionally replaced by —NR y —, —N(R y )C(O)—, —N(R y )C(O)N(R y )—, —N(R y )C(S)N(R y )—, —C(O)N(R y )—, —N(R y )SO 2 —, —SO 2 N(R y )—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, cycloalkylene, heterocyclylene, arylene, or heteroarylene; wherein R y is hydrogen, C 1-6 alkyl, or —C(O)C 1-6 alkyl; and R P is selected from the group consisting of ligands, radionuclides, fluorescent dyes, chemiluminescent agents, microparticles, enzymes, calorimetric labels, magnetic labels, and haptens. 2. A compound of Formula (I): or a salt thereof, wherein R 1 is hydrogen, —C(O)NHR 8 , —CH 2 OR 9 , or —C(O)OR 9 ; R 2 and R 3 are independently hydrogen, optionally substituted aliphatic, —OR 9 , —N(R 8 ) 2 , or —C(O)NHR 8 ; R 4 is hydrogen or —WR 4a ; W is —O— or —NH—; R 4a is hydrogen, a hydroxyl protecting group, optionally substituted aliphatic, —C(O)R 10 , —C(O)NHR 8 , —C(═NR 8 )NHR 8 , or —C(O)OR 9 ; R 5 is hydrogen or —NHR 8 ; R 6 is hydrogen, —CH 3 , —CH 2 OR 9 , or —CH 2 OR CX ; wherein R CX is a carbohydrate moiety; R 7 is hydrogen, —OR 9 , or —N(R 8 ) 2 ; each R 8 is independently hydrogen, an amino protecting group, —C(O)R 10 , optionally substituted aliphatic, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, or two R 8 groups on the same nitrogen may be taken together to form an optionally substituted heterocyclyl; each R 9 is independently hydrogen, a

Assignees

Inventors

Classifications

  • Phosphates; Phosphites; Polyphosphates · CPC title

  • Acyclic or carbocyclic radicals, substituted by hetero rings · CPC title

  • C12Q1/48Primary

    involving transferase · CPC title

  • cell-free systems · CPC title

  • C07H13/12Primary

    by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10106833B2 cover?
The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).
Who is the assignee on this patent?
Harvard College
What technology area does this patent fall under?
Primary CPC classification C12Q1/48. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).